{
  "id": 127224,
  "name": "MERCK & CO., INC",
  "slug": "merck-co-inc",
  "state": "DC",
  "description": "Prescription medicines, vaccines, and biologic therapies",
  "totalSpending": 1570000,
  "filings": 27,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 150000
    },
    {
      "year": 2019,
      "income": 100000
    },
    {
      "year": 2020,
      "income": 200000
    },
    {
      "year": 2021,
      "income": 200000
    },
    {
      "year": 2022,
      "income": 200000
    },
    {
      "year": 2023,
      "income": 200000
    },
    {
      "year": 2024,
      "income": 100000
    },
    {
      "year": 2025,
      "income": 200000
    }
  ],
  "firms": [
    "TIBER CREEK GROUP"
  ],
  "lobbyists": [
    "JONATHON JONES",
    "ANDREW MCKECHNIE",
    "JOHN GONZALEZ",
    "COREY MALMGREN"
  ],
  "issues": [
    "HCR",
    "PHA",
    "MMM",
    "TRD",
    "CPT",
    null
  ],
  "sampleDescriptions": [
    "Issues related to vaccines; issues related to pharmaceutical pricing and transparency; issues related to the Hospital Outpatient Prospective Payment System final rule.",
    "Issues related to vaccines.",
    "Issues related to pharmaceutical pricing and transparency. P.L. 115-123 - Bipartisan Budget Act of 2018, provisions relating to the Part D coverage gap.",
    "Issues related to pharmaceutical pricing and transparency. Provisions relating to the Part D coverage gap.",
    "Issues related to vaccines; issues related to pharmaceutical pricing and transparency.",
    "Issues related to pharmaceutical pricing and transparency.",
    "Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing.",
    "Issues related to the United States-Mexico-Canada-Agreement (USMCA)",
    "Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues.",
    "Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues.",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act",
    "Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act",
    "Issues relating to pharmaceutical pricing and transparency. Provisions relating to Part D Pricing Reform. Proposal to eliminate Medicaid inflationary cap. Issues relating to biosimilars coverage & pricing. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act",
    "Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; HR 4100/S 1712, DISARM Act; Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act; Executive Order on Lowering Drug Prices by Putting America First",
    "Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain. S. 2543 - The Prescription Drug Price Reduction Act. H.R. 3 - Lower Drug Costs Now Act of 2019. HR 4100/S 1712, DISARM Act; Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act; Executive Order on Lowering Drug Prices by Putting America First; H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act; Issues related to the Medicaid Drug Rebate Program",
    "Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.",
    "Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain.",
    "Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform; Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs; H.R. 1319 - American Rescue Plan Act of 2021, SEC. 9816, SUNSET OF LIMIT ON MAXIMUM REBATE AMOUNT FOR SINGLE SOURCE DRUGS AND INNOVATOR MULTIPLE SOURCE DRUGS."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 33,
  "trajectory": "growing",
  "yearsActive": 8,
  "avgAnnualSpending": 168750,
  "peakYear": 2020,
  "lobbyistCount": 4,
  "firmCount": 1,
  "issueCount": 5
}